PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Matthew T. Ballo, MD, FACR - Modernizing Your Radiation Oncology Practice With Tumor Treating Fields and Other Novel Multimodal Strategies: Understanding the Science, Evidence, and Practical Aspects Across a Range of Solid Tumors
Go online to PeerView.com/KGF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies are revolutionizing the therapeutic management of solid tumors. This new modality of alternating electric fields therapy is FDA approved in GBM and MPM and is paving the way for improved outcomes in other solid tumors. As this previously unrecognized antimitotic therapy with a unique mode of delivery continues to be combined with conventional cancer therapies, including surgery, systemic therapy, and radiation therapy, the oncology community will benefit from understanding the practical implications in the multidisciplinary management of cancer. This activity will feature a review of the cutting-edge advancements in cancer devices, as well as expert insights and case discussions on the appropriate care strategies for patients being treated with new modalities like TTFields therapy. And, the expert panel will review key safety and efficacy evidence on innovative and emerging multimodal strategies for the treatment of GBM, MPM, NSCLC, pancreatic cancer, and other GI and gynecologic tumors. Upon completion of this activity, participants should be better able to: Summarize the mechanistic rationale for the use of novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Evaluate the key safety and efficacy evidence on innovative strategies available for the therapeutic management of GBM and MPM, Review the most recent evidence and ongoing clinical trials on novel therapeutic modalities, including combining TTFields with systemic therapy, radiotherapy, or other modalities, in multiple tumor types such as lung, pancreatic, gastric, liver, and ovarian cancers, across different treatment settings, Develop strategies to effectively integrate novel technologies into the therapeutic management of patients with cancer, including through appropriate adverse event management and enrollment in clinical trials.